Considering that hematopoietic stem and progenitor cells (HSPCs) are important for MDS prognosis and treatment, we performed an in silico analysis of CD34+ gene expression and verified that CEP55 was reduced and both TLN1 and MSN expressions were increased in the bone marrow of MDS patients without any stratification. This evidence concerns the gene CEP55 and myelodysplastic syndrome.